Low blood level of tumour suppressor miR-5193 as a target of immunotherapy to PD-L1 in gastric cancer-Reference-Cited by-同舟云学术

Low blood level of tumour suppressor miR-5193 as a target of immunotherapy to PD-L1 in gastric cancer

Published:2023-12-26 Issue: Volume: Page:
ISSN:0007-0920
Container-title:British Journal of Cancer
language:en
Short-container-title:Br J Cancer

Author:

Kamiya Hajime,Komatsu Shuhei^ORCID,Takashima Yusuke,Ishida Ryo,Arakawa Hiroshi,Nishibeppu Keiji,Kiuchi Jun,Imamura Taisuke,Ohashi Takuma,Shimizu Hiroki,Arita Tomohiro^ORCID,Konishi Hirotaka,Shiozaki Atsushi,Kubota Takeshi,Fujiwara Hitoshi,Yagyu Shigeki,Iehara Tomoko,Otsuji Eigo

Publisher

Springer Science and Business Media LLC

Subject

Cancer Research,Oncology

Link

https://www.nature.com/articles/s41416-023-02532-3.pdf

Reference46 articles.

1. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68:394–424.

2. Bachy E, Coiffier B. Anti-PD1 antibody: a new approach to treatment of lymphomas. Lancet Oncol. 2014;15:7–8.

3. Lipson EJ, Sharfman WH, Drake CG, Wollner I, Taube JM, Anders RA, et al. Durable cancer regression off-treatment and effective reinduction therapy with an anti-PD-1 antibody. Clin Cancer Res. 2013;19:462–8.

4. Robert C, Long GV, Brady B, Dutriaux C, Maio M, Mortier L, et al. Nivolumab in previously untreated melanoma without BRAF mutation. N Engl J Med. 2015;372:320–30.

5. Reck M, Rodríguez-Abreu D, Robinson AG, Hui R, Csőszi T, Fülöp A, et al. Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer. N Engl J Med. 2016;375:1823–33.

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Predictive Factors of Immunotherapy in Gastric Cancer: A 2024 Update;Diagnostics;2024-06-13

2. Circ_0027791 contributes to the growth and immune evasion of hepatocellular carcinoma via the miR‐496/programmed cell death ligand 1 axis in an m6A‐dependent manner;Environmental Toxicology;2024-03-28

3. MicroRNAs as regulators of immune checkpoints in cancer immunotherapy: targeting PD-1/PD-L1 and CTLA-4 pathways;Cancer Cell International;2024-03-10